Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.55 |
| ▸ | CCNC | P24863 | 3/20 | 0.47 |
| ▸ | CDK8 | P49336 | 3/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 7/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.46 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.45 |
| ▸ | AURKA | O14965 | 2/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.44 |
| ▸ | TTK | P33981 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17452928 | 0.90 | ROCK2 (0.54) | USP30CCNCCDK8ROCK2ROCK1 | |
| SCHEMBL19902593 | 0.89 | USP30 (0.54) | USP30CCNCCDK8ROCK2ROCK1 | |
| SCHEMBL19902380 | 0.87 | ROCK2 (0.62) | ROCK2ROCK1 | |
| SCHEMBL19902605 | 0.86 | CCNC (0.55) | CCNCCDK8ROCK2ROCK1RIPK2 | |
| SCHEMBL19902506 | 0.83 | USP30 (0.52) | USP30CCNCCDK8ROCK2ROCK1 | |
| SCHEMBL19902498 | 0.83 | ROCK2 (0.43) | ROCK2ROCK1 | |
| SCHEMBL19902428 | 0.80 | USP30 (0.44) | USP30CCNCCDK8ROCK2RIPK2 | |
| SCHEMBL19902606 | 0.80 | USP30 (0.44) | USP30CCNCCDK8ROCK2RIPK2 | |
| SCHEMBL19902358 | 0.80 | PSEN1 (0.51) | ROCK2RIPK2 | |
| SCHEMBL19902412 | 0.80 | ROCK2 (0.43) | USP30CCNCCDK8ROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180155296-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2018-06-07 | — | — | US | disclosed |
| US-9902702-B2 | Spirocycloheptanes as inhibitors of rock | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180155296-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | ROCK1, MYLK, ROCK2 | USP30 3527/4885CCNC 1995/4885CDK8 1196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.